'Longevity as a service': Insilico spins off AI biotech that trains deep learning on anti-aging treatments

1 min read Original article ↗

Since its in­cep­tion in 2014, In­sil­i­co has racked up deal af­ter deal on the promise that ar­ti­fi­cial in­tel­li­gence can has­ten drug de­vel­op­ment, tout­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER